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Case Report
Primary urethral squamous
cell carcinoma: a unique
manifestation of a
penile tumor
Isabelle Antwerpen1, Lukas Gstrein1,2,
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Stephen Wyler1 and Matthias Walter1,5
Abstract
This case report describes a unique manifestation of a primary urethral squamous cell carcinoma
(SCC) as the underlying pathology in an 80-year-old male patient who underwent partial penec-
tomy due to an enlarging penile mass. Persistent pain in the right knee was discovered to be a
pathologic fracture using magnetic resonance imaging. Computed tomography-guided
biopsy confirmed metastatic SCC. Whole-body positron emission tomography revealed systemic
dissemination to multiple sites. Orthopedic knee replacement was performed in combination
with local radiotherapy. Palliative chemotherapy was rejected due to poor performance status.
Primary urethral SCC is rare and an uncommon cause of advanced penile cancer. These findings
could be of great interest to clinicians for two reasons. First, a tumor’s appearance can be
misleading. Consequently, histological work-up in accordance with clinical guidelines is necessary
for accurate diagnosis. Second, a more comprehensive investigation is required when
clinical symptoms persist despite the use of conventional treatment. Our case is an instance in
which persistent pain masked the presence of downstream metastasis. We believe that these
aforementioned points are of significant clinical importance and present a salient learning
opportunity.
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Introduction
Penile cancer is rare (incidence <1/100,000
men).1 There are several well-known risk
factors associated with the development of
penile cancer, including phimosis, smoking,
multiple sexual partners, and early age at
first intercourse.1 Furthermore, human
papilloma virus (HPV)-related carcinogene-
sis is reported in more than one-third of
all cases.1
Although penile cancer might be expected
to be the underlying cause of a penile mass,
a primary urethral carcinoma as the origin
can be revealed by histology. Primary ure-
thral carcinoma has several predisposing fac-
tors in common with penile cancer but is
6 times less frequent (incidence approximate-
ly 1.6/1,000,000 men).2 Although squamous
cell carcinoma (SCC) constitutes the vast
majority (>95%) of penile cancer, it com-
prises approximately 20% of all primary
urethral carcinomas.1,2
Herein, we present an unusual case of a
man in whom a primary urethral SCC was
the underlying cause of penile cancer.
Case presentation
An 80-year-old man presented with symp-
tomatic urinary retention due to an enlarg-
ing penile mass. In the preceding 3 months,
the patient had experienced intermittent
gross hematuria. Furthermore, he reported
the presence of non-traumatic pain in the
right knee during the prior 2 weeks; notably,
he complained of load-dependent pain cor-
responding to an 8 on a numeric rating scale
(i.e., from 0¼no pain at all, to 10¼most
pain imaginable). Physical examination also
revealed palpable lymph nodes in the right
groin. Although the patient was fully aware
of these changes, he felt embarrassed and
delayed medical attention until his condition
became almost unbearable for him.
First, a percutaneous suprapubic cystos-
tomy was placed, which immediately
relieved urinary retention. Then, conven-
tional X-rays of the right knee were con-
ducted; however, these did not show any
pathology (Figure 1a). With adequate anal-
gesia, the patient was able to strain his right
leg without any restriction. The following
day, tumor staging using computed tomog-
raphy showed nodal enlargement in the
right groin, but found no organ or other
nodal metastasis (cT3 cN2 cM0). Partial
penectomy was performed shortly after.
Histology (Figure 2a–c) revealed a pT3
G2 primary urethral SCC.
A couple of days after the surgery, the
patient reported persistent pain in the
right knee despite the administration of
adequate analgesia. Thus, magnetic reso-
nance imaging (Figure 1b) was performed,
which revealed a pathologic fracture of the
distal femur. Computed tomography-guided
biopsy verified metastasis (Figure 2d–f).
Using whole-body positron emission tomog-
raphy (Figure 1c), systemic dissemination to
multiple sites became evident (i.e., pT3 cN2
cM1). Considering all findings, we discussed
this case at length during our multidiscipli-
nary tumor board. As a result, total knee
arthroplasty was performed 2 weeks
later, in combination with local radiother-
apy for presenting symptomatology and
ambulation. Palliative chemotherapy was
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also considered; however, it was not initi-
ated due to the patient’s poor performance
status (i.e., grade 3 of the Eastern
Cooperative Oncology Group, ECOG).3
Thus, the patient was discharged but fol-
lowed up regularly for replacement of the
suprapubic catheter and clinical evaluation.
Although his performance status improved
to an ECOG grade 2 over the next
2 months, the patient declined palliative
chemotherapy. Four months after initial
presentation, he underwent palliative radio-
therapy to manage symptomatic bilateral
lymph node enlargement of the groin. As
a consequence of his progressive disease,
the patient’s condition deteriorated signifi-
cantly and he was placed in a hospice to
receive the best palliative care possible.
The patient succumbed to his illness,
6 months after initial presentation.
Discussion
Primary urethral SCC is a very uncommon
cause of penile tumors.2 Whereas primary
urethral carcinoma is very unlikely to occur
in adults under the age of 45 years, its high-
est incidence rate is often reported in indi-
viduals at 75 years and older.2,4 In men,
who are approximately three times more
frequently affected than women, primary
urethral SCC can develop from predispos-
ing factors such as urethral strictures,
chronic urethral irritation and inflamma-
tion, or sexually transmitted diseases,
such as HPV-associated condylomata.2
Although chronic inflammation and HPV
infection are also common risk factors for
penile cancer,1 the prevalence of HPV in the
male urethra is much lower.5
The European Association of Urology
(EAU) guidelines on primary urethral car-
cinoma recommend diagnostic urethrocys-
toscopy with biopsy for primary assessment
[level of evidence (LE) 3, grade of recom-
mendation (GR) B], as crucial information
regarding tumor extent and location, as
well as subtype classification, can be deter-
mined through histological examination.2
Interestingly, in contrast to penile cancer,
Figure 1. a: Plain film radiographs (anterior posterior view) of the right knee demonstrating no obvious
pathology. b: Coronary T1-weighted magnetic resonance imaging of the right knee showing extensive
metastasis with cortical infiltration and a fracture line of the medial femur condyle (arrows). c: Whole-body
positron emission tomography scan displaying dissemination to multiple sites: bilateral inguinal lymph nodes,
right femur, right fibula, right tibia, and right fourth metatarsal bone.
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SCC is a less common histological type (i.e.,
approximately one in four). “Urothelial
carcinoma of the urethra” is the predomi-
nant histological type of primary urethral
cancer.2 Given the large penile mass, we
expected that histological examination
would reveal the patient to have a penile
SCC. Therefore, we refrained from per-
forming a diagnostic urethrocystoscopy
with biopsy.
Comprehensive staging (i.e., computed
tomography of the thorax and abdomen)
is advised (LE 3, GR B) in all patients
with invasive disease (>cT1) to assess
whether metastases are present.2 In our
case, computed tomography of the thorax
and abdomen did not reveal any organ
metastasis, although it showed local nodal
enlargement. Interestingly, after the use of
MRI for further exploration of the patient’s
painful right knee, an uncommon site of
metastasis was detected. Considering that
osteoarthritis is the number one cause of
knee pain in adults over 65 years of age,6
we did not expect to observe a pathological
fracture as the cause for the patient’s
painful right knee. After performance of
whole-body positron emission tomography,
Figure 2. Representative microscopic images of primary urethral squamous cell carcinoma and femoral
bone metastasis using hematoxylin and eosin staining. a: Partial penectomy specimen – overview with
squamous cell carcinoma (original magnification, OM). b: Partial penectomy specimen with blood vessel
invasion of squamous cell carcinoma (10 OM). c: Partial penectomy specimen with squamous cell carci-
noma in situ (left side) and penile invasion (right side) (10 OM). d: Core bone biopsy overview with
metastasis (arrow) of the right femoral bone (OM). e: Femoral bone metastasis with cortical involvement
(2 OM). f: Femoral bone metastasis with focal spindle cell-like morphology (20 OM).
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systemic dissemination to multiple bony
sites became evident. While less frequently
reported in primary urethral SCC, regional
spread of penile cancer is well-known; the
most common routes of systemic spread
after passage through regional nodes are
pelvic and retroperitoneal nodes, followed
by liver and lung.1
Radiotherapy (LE 3, GR C) or urethrec-
tomy and urethra-sparing surgery (LE 3,
GR B) are recommended treatment strate-
gies for the management of primary ure-
thral SCC in localized stages of cancer.2
Depending on performance status, patients
with locally advanced SCC might benefit
from preoperative chemoradiotherapy (LE
4, GR C).2,7,8 Depending on tumor stage
and the patient’s performance status, radio-
therapy or radical surgery, in combination
with chemotherapy, are recommended treat-
ment strategies. For superficial non-invasive
penile cancer (Tis), topical chemotherapy,
circumcision, laser therapy, or glans resur-
facing have all been shown to be beneficial.1
While organ-sparing treatment (including
radiotherapy for lesions <4 cm) is appropri-
ate for localized invasive penile cancer (i.e.,
T2), partial or total penectomy in combi-
nation with neoadjuvant chemotherapy or
palliative radiotherapy is recommended for
more invasive stages of disease (i.e., T3/T4).1
Although associated with a high burden of
morbidity (up to 50%), radical inguinal lym-
phadenectomy with adjuvant chemotherapy
can be considered in patients with penile
cancer and palpable inguinal lymph nodes
(cN1/cN2).1
When providing patients with treatment
options, disease-specific risk factors for sur-
vival should be considered. There are mul-
tiple predictors for survival in cases of
primary urethral carcinoma (LE 3) related
to patient (age and ethnicity) and tumor
(size, location, stage and grade, nodal
stage, presence of distant metastasis, and
histological type) characteristics.2 In con-
trast, the outcome for patients with penile
cancer primarily depends on the histologi-
cal subtype of the SCC and its association
with HPV (in addition to tumor
characteristics).1
In prior studies, the 5-year overall sur-
vival of primary urethral carcinoma
ranged from 46%9 to 54%,10 with a
5-year overall cancer-specific survival of
68%.4 When stratified by primary T stage,
5-year overall survival ranged from 63%
(cT1) to 29% (cT3).9 Although subject
to temporal fluctuations,11 the 5-year over-
all survival of patients with penile cancer
was higher (i.e., between 65%12 and
70%13) than that of patients with primary
urethral carcinoma. Independent of the
type of cancer (penile or primary urethral),
SCC has the highest 5-year relative survival
(70% and 69%, respectively), compared
with adenocarcinoma (44% and 48%,
respectively) or transitional cell carcinoma
of the urethra (52%).10 These findings were
confirmed for primary urethral carcinoma,
such that SCC had a longer mean survival
time than transitional cell carcinoma and
adenocarcinoma (i.e., 71 vs. 48 vs. 38
months, respectively).9 In addition, patients
with HPV-positive penile SCC had signifi-
cantly better 5-year disease-specific survival
than those reported as HPV-negative (93%
versus 78%).14 Despite the favorable over-
all outcome for patients with SCC, survival
significantly decreased with age (>75 years)
and stage progress, as evident in our
case.12,13 Given the small number of
patients worldwide and because of the
lack of standardized follow-up guidelines,
predictions of long-term outcome for
patients with primary urethral carcinoma
remain difficult.
Conclusion
This case report describes a unique manifes-
tation of a primary urethral SCC, which is a
rare and uncommon cause of an advanced
penile tumor. These findings could be of
Antwerpen et al. 5
great interest to clinicians for two reasons.
First, a tumor’s appearance can be mislead-
ing. Consequently, histological work-up, as
recommended by clinical guidelines, is nec-
essary for accurate diagnosis. Second, if
there is a discrepancy between clinical
symptoms and the underlying disease, a
more comprehensive investigation is
required. Our case demonstrates a corre-
sponding example, wherein persistent knee
pain was revealed as an unusual down-
stream metastasis of a primary urethral
SCC. We believe that these aforementioned
points are of considerable clinical impor-
tance and present an important learning
opportunity.
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